Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Sales (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Return on Sales data on record, last reported at 0.04% in Q4 2025.

  • For Q4 2025, Return on Sales rose 31.0% year-over-year to 0.04%; the TTM value through Dec 2025 reached 0.14%, up 48.0%, while the annual FY2025 figure was 0.15%, 48.0% up from the prior year.
  • Return on Sales reached 0.04% in Q4 2025 per TARS's latest filing, up from 0.11% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.33% in Q2 2021 and bottomed at 42.87% in Q4 2021.
  • Average Return on Sales over 5 years is 7.06%, with a median of 1.03% recorded in 2024.
  • The widest YoY moves for Return on Sales: up 4151bps in 2022, down -3712bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 42.87% in 2021, then soared by 97bps to 1.36% in 2022, then tumbled by -138bps to 3.25% in 2023, then soared by 89bps to 0.35% in 2024, then soared by 88bps to 0.04% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.04% in Q4 2025, 0.11% in Q3 2025, and 0.2% in Q2 2025.